Related Experiment Video
Updated: Feb 7, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer.
Lakisha Moore-Smith1, Andres Forero-Torres2, Erica Stringer-Reasor3
1Department of Medicine, Brookwood Baptist Health - Princeton, 833 Princeton Avenue, POB III Suite 200, Birmingham, AL 35211-1311, USA.
Triple-negative breast cancer (TNBC) remains a deadly subtype with few treatment options. Genomic profiling offers new hope for developing targeted therapies to improve patient outcomes.
Area of Science:
- Oncology
- Genomics
- Cancer Research
Background:
- Breast cancer is a leading cause of cancer death in women.
- Triple-negative breast cancer (TNBC) presents unique challenges due to limited targeted treatment options compared to other subtypes.
- Advances in targeted therapies have largely excluded TNBC, highlighting an unmet clinical need.
Purpose of the Study:
- To explore the potential of genomic profiling in identifying novel therapeutic targets for TNBC.
- To investigate the efficacy of personalized targeted agents in the neoadjuvant setting for TNBC patients.
- To understand mechanisms of resistance to current and novel therapies in TNBC.
Main Methods:
- Genomic profiling of TNBC tumors to identify actionable mutations and molecular alterations.
- Application of personalized targeted agents in the neoadjuvant treatment setting.
- Analysis of treatment response and resistance mechanisms through molecular and clinical data.
Main Results:
- Genomic profiling revealed promising molecular targets for TNBC.
- Personalized therapies demonstrated potential in the neoadjuvant setting, warranting further investigation.
- Insights into resistance mechanisms were gained, crucial for future treatment strategies.
Conclusions:
- Genomic profiling is a valuable tool for advancing TNBC treatment.
- Targeted therapies in the neoadjuvant setting hold promise for improving TNBC patient outcomes.
- Further research into molecular-based therapies is essential for overcoming treatment resistance in TNBC.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
Negative Regulator Molecules
Positive, Negative, and Zero Work
Sustainable Development

